• Publications
  • Influence
Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry
Clinical pharmacokinetic and pharmacodynamic data suggest the efficacy and once daily dosing of gemigliptin and further development of combination therapy is on-going.
Taxonomic revision of Chordaria flagelliformis (Chordariales, Phaeophyceae) including novel use of the intragenic spacer region of rDNA for phylogenetic analysis
Molecular phylogenetic analyses using the 5.8S-5S IGS region for molecular phylogenetic analysis in any organism showed C. flagelliformis was concluded to exhibit great morphological plasticity and to contain some specimens that are unbranched, whereas f.
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Gemigliptin is shown to be an optimized DPP-4 inhibitor in terms of efficacy, safety, and patient compliance for treatment of type 2 diabetes mellitus and its potential benefits in clinical practice are discussed.
Possible surface carbohydrates involved in signaling during conjugation process in Zygnema cruciatum monitored with fluorescein isothiocyanate‐lectins (Zygnemataceae, Chlorophyta)
Blocking experiments with various lectins showed that these SBA‐ and PNA‐specific glycoconjugates might be involved in the signaling between male and female papillae.
Characterization of hydrophobized pullulan with various hydrophobicities.
Probing rhodopsin-transducin interactions by surface modification and mass spectrometry.
It is demonstrated that the surface exposure of the acetylation sites was reduced by the conformational change associated with light activation, and that binding of G(t)alpha(340-350) blocks acetylated sites on cytoplasmic loops 1, 2, and 4 of Rh*.
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
This first-time-in-human study provides evidence of the pharmacological activity of LC15-0444 in humans, by using dipeptidyl peptidase IV activity and active glucagon-like peptide-1 concentrations to investigate the pharmacokinetic and pharmacodynamic profiles after multiple oral ascending doses of the selective inhibitor with potential for the treatment of Type 2 diabetes.
Clonazepam release from poly(DL-lactide-co-glycolide) nanoparticles prepared by dialysis method
In the effect of drug loading contents on the particle size distribution, PLGA nanoparticles were monomodal patterns with narrow size distribution in the empty and lower drug loading nanoparticles whereas bi- or trimodal pattern was showed in the higher drug loading ones.